PMID- 23940580 OWN - NLM STAT- MEDLINE DCOM- 20140305 LR - 20220321 IS - 1932-6203 (Electronic) IS - 1932-6203 (Linking) VI - 8 IP - 8 DP - 2013 TI - Increased cellular senescence and vascular rarefaction exacerbate the progression of kidney fibrosis in aged mice following transient ischemic injury. PG - e70464 LID - 10.1371/journal.pone.0070464 [doi] LID - e70464 AB - Recent findings indicate that elderly patients with acute kidney injury (AKI) have an increased incidence of progression to chronic kidney disease (CKD) due to incomplete recovery from an acute insult. In the current study, a co-morbid model of AKI was developed to better mimic the patient population and to investigate whether age exacerbates the fibrosis and inflammation that develop in the sequelae of progressive kidney disease following acute injury. Young (8-10 weeks) and aged (46-49 weeks) C57BL/6 mice were subjected to 30 min bilateral renal ischemia-reperfusion (I/R) to induce AKI. The aged animals have greater mortality and prolonged elevation of plasma creatinine correlating with less tubular epithelial cell proliferation compared to the young. Six weeks post-reperfusion, interstitial fibrosis is greater in aged kidneys based on picrosirius red staining and immunolocalization of cellular fibronectin, collagen III and collagen IV. Aged kidneys 6 weeks post-reperfusion also express higher levels of p53 and p21 compared to the young, correlating with greater increases in senescence associated (SA) beta-galactosidase, a known marker of cellular senescence. A higher influx of F4/80(+) macrophages and CD4(+) T lymphocytes is measured and is accompanied by increases in mRNA of monocyte chemoattractant protein-1 (MCP-1) and tumor necrosis factor-alpha (TNF-alpha). Importantly, microvascular density is significantly less, correlating with an increase in nitro-tyrosine, a marker of oxidative stress. Collectively, these data demonstrate that prolonged acute injury in the aged animals results in an accelerated progression of kidney disease in a chronic state. FAU - Clements, Meghan E AU - Clements ME AD - Tissue Protection and Repair Unit, Genzyme R&D, Genzyme, a division of Sanofi, Framingham, Massachusetts, USA. FAU - Chaber, Christopher J AU - Chaber CJ FAU - Ledbetter, Steven R AU - Ledbetter SR FAU - Zuk, Anna AU - Zuk A LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20130805 PL - United States TA - PLoS One JT - PloS one JID - 101285081 RN - 0 (Chemokine CCL2) RN - 0 (Tumor Necrosis Factor-alpha) SB - IM MH - Acute Kidney Injury/metabolism/*pathology MH - Animals MH - Cellular Senescence/*physiology MH - Chemokine CCL2/metabolism MH - Fibrosis/metabolism/*pathology MH - Kidney/metabolism/*pathology MH - Male MH - Mice MH - Mice, Inbred C57BL MH - Reperfusion Injury/metabolism/*pathology MH - Tumor Necrosis Factor-alpha/metabolism PMC - PMC3734312 COIS- Competing Interests: The authors have read the journal's policy and have the following conflicts: All authors are employees of Genzyme, a Sanofi company. The authors do not have any other relevant declarations relating to patents, products in development, or marketed products. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials. EDAT- 2013/08/14 06:00 MHDA- 2014/03/07 06:00 PMCR- 2013/08/05 CRDT- 2013/08/14 06:00 PHST- 2012/12/07 00:00 [received] PHST- 2013/06/24 00:00 [accepted] PHST- 2013/08/14 06:00 [entrez] PHST- 2013/08/14 06:00 [pubmed] PHST- 2014/03/07 06:00 [medline] PHST- 2013/08/05 00:00 [pmc-release] AID - PONE-D-12-38766 [pii] AID - 10.1371/journal.pone.0070464 [doi] PST - epublish SO - PLoS One. 2013 Aug 5;8(8):e70464. doi: 10.1371/journal.pone.0070464. Print 2013.